Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis

Sponsor
National and Kapodistrian University of Athens
Study ID
NCT07169682
Status
Completed

Conditions

  • Atherosclerosis
  • Cardiovascular Disease
  • Psoriasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Data on the antiatherogenic effect of IL23 inhibitors are sparse. This study aimed to assess the impact of one-year treatment with an IL17 or IL23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis. This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL17 inhibitor or an IL23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).

Key Dates

First listed
Sep 12, 2025
Start date
Sep 1, 2021
Status verified
Sep 2025
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024

Study Design

Enrollment
66 participants (actual)

Arms

  • Arm: Group 1
    IL17 inhibitor
  • Arm: Group 2
    IL23 inhibitor
  • Arm: Group 3
    conventional systemic agent or apremilast

Primary Outcome Measure

change of pulse wave velocity (PWV) from baseline to week 24 and 52 [ Time Frame: from enrollment to the end of treatment at week 52 ]

Related Studies